Literature DB >> 23055569

Inhibition of alpha interferon (IFN-α)-induced microRNA-122 negatively affects the anti-hepatitis B virus efficiency of IFN-α.

Junli Hao1, Wensong Jin, Xinghui Li, Saifeng Wang, Xiaojun Zhang, Hongxia Fan, Changfei Li, Lizhao Chen, Bin Gao, Guangze Liu, Songdong Meng.   

Abstract

Alpha interferon (IFN-α)-based therapy can effectively treat chronic hepatitis B virus (HBV) infection, which causes life-threatening complications. Responses to IFN-α therapy vary greatly in chronic hepatitis B (CHB) patients, but underlying mechanisms are almost unknown. In this study, we found that IFN-α treatment induced a marked decrease of microRNA-122 (miR-122) expression in hepatocytes. We next showed that IFN-α-induced miR-122 downregulation was only partly due to transcriptional suppression. One IFN-stimulated gene (ISG), NT5C3, which was identified as a miR-122 target, efficiently inhibited miR-122 by binding and sequestering miR-122 with its mRNA 3'-untranslated region (3'-UTR), indicating that this ISG is involved in IFN-α-mediated miR-122 suppression. Notably, the inhibitory effect of IFN-α on miR-122 was completely abolished by blocking IFN-α-induced upregulation of NT5C3 mRNA expression by RNA interference (RNAi). Meanwhile, we observed that miR-122 dramatically inhibited HBV expression and replication. Finally, we showed that IFN-α-mediated HBV-inhibitory effects could be enhanced significantly by blocking IFN-α-induced downregulation of miR-122. We therefore concluded that IFN-α-induced inhibition of miR-122 may negatively affect the anti-HBV function of IFN-α. These data provide valuable insights for a better understanding of the antiviral mechanism of IFN-α and raise further potential interest in enhancing its anti-HBV efficacy.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 23055569      PMCID: PMC3536426          DOI: 10.1128/JVI.01710-12

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  51 in total

Review 1.  miR-122, a paradigm for the role of microRNAs in the liver.

Authors:  Muriel Girard; Emmanuel Jacquemin; Arnold Munnich; Stanislas Lyonnet; Alexandra Henrion-Caude
Journal:  J Hepatol       Date:  2008-02-12       Impact factor: 25.083

2.  Reciprocal effects of micro-RNA-122 on expression of heme oxygenase-1 and hepatitis C virus genes in human hepatocytes.

Authors:  Ying Shan; Jianyu Zheng; Richard W Lambrecht; Herbert L Bonkovsky
Journal:  Gastroenterology       Date:  2007-08-03       Impact factor: 22.682

3.  APOBEC3-independent interferon-induced viral clearance in hepatitis B virus transgenic mice.

Authors:  Priscilla Turelli; Alexandra Liagre-Quazzola; Bastien Mangeat; Sonia Verp; Stephanie Jost; Didier Trono
Journal:  J Virol       Date:  2008-04-23       Impact factor: 5.103

4.  Induction of antiviral cytidine deaminases does not explain the inhibition of hepatitis B virus replication by interferons.

Authors:  Stéphanie Jost; Priscilla Turelli; Bastien Mangeat; Ulrike Protzer; Didier Trono
Journal:  J Virol       Date:  2007-07-25       Impact factor: 5.103

5.  The level of hepatitis B virus replication is not affected by protein ISG15 modification but is reduced by inhibition of UBP43 (USP18) expression.

Authors:  Jung-Hwan Kim; Jiann-Kae Luo; Dong-Er Zhang
Journal:  J Immunol       Date:  2008-11-01       Impact factor: 5.422

6.  Role of ISGF3 in modulating the anti-hepatitis B virus activity of interferon-alpha in vitro.

Authors:  Quan Zhang; Yan Wang; Lai Wei; Dong Jiang; Jiang Hua Wang; Hui Ying Rao; Ling Zhu; Hongsong Chen; Ran Fei; Xu Cong
Journal:  J Gastroenterol Hepatol       Date:  2007-06-07       Impact factor: 4.029

7.  Decreased levels of microRNA miR-122 in individuals with hepatitis C responding poorly to interferon therapy.

Authors:  Magdalena Sarasin-Filipowicz; Jacek Krol; Ilona Markiewicz; Markus H Heim; Witold Filipowicz
Journal:  Nat Med       Date:  2009-01-04       Impact factor: 53.440

8.  Early serum HBsAg drop: a strong predictor of sustained virological response to pegylated interferon alfa-2a in HBeAg-negative patients.

Authors:  Rami Moucari; Vincent Mackiewicz; Olivier Lada; Marie-Pierre Ripault; Corinne Castelnau; Michelle Martinot-Peignoux; Agnes Dauvergne; Tarik Asselah; Nathalie Boyer; Pierre Bedossa; Dominique Valla; Michel Vidaud; Marie-Hélène Nicolas-Chanoine; Patrick Marcellin
Journal:  Hepatology       Date:  2009-04       Impact factor: 17.425

9.  Interferon and lamivudine vs. interferon for hepatitis B e antigen-positive hepatitis B treatment: meta-analysis of randomized controlled trials.

Authors:  Dan Rudin; Sooraj M Shah; Alexander Kiss; Robert V Wetz; Vincent M Sottile
Journal:  Liver Int       Date:  2007-11       Impact factor: 5.828

Review 10.  Interferon-inducible antiviral effectors.

Authors:  Anthony J Sadler; Bryan R G Williams
Journal:  Nat Rev Immunol       Date:  2008-07       Impact factor: 53.106

View more
  21 in total

Review 1.  Present and future therapies of hepatitis B: From discovery to cure.

Authors:  T Jake Liang; Timothy M Block; Brian J McMahon; Marc G Ghany; Stephan Urban; Ju-Tao Guo; Stephen Locarnini; Fabien Zoulim; Kyong-Mi Chang; Anna S Lok
Journal:  Hepatology       Date:  2015-10-27       Impact factor: 17.425

2.  Reply to miR-122, IL28B genotype and the response to interferon in chronic hepatitis C virus infection.

Authors:  Markus Heim
Journal:  Nat Rev Immunol       Date:  2013-12       Impact factor: 53.106

3.  miR-122, IL28B genotype and the response to interferon in chronic hepatitis C virus infection.

Authors:  Jae Il Shin; Michael Eisenhut
Journal:  Nat Rev Immunol       Date:  2013-12       Impact factor: 53.106

Review 4.  MiR-122 in hepatitis B virus and hepatitis C virus dual infection.

Authors:  Kyoungsub Song; Chang Han; Srikanta Dash; Luis A Balart; Tong Wu
Journal:  World J Hepatol       Date:  2015-03-27

5.  Development of a Novel Site-Specific Pegylated Interferon Beta for Antiviral Therapy of Chronic Hepatitis B Virus.

Authors:  Masataka Tsuge; Takuro Uchida; Nobuhiko Hiraga; Hiromi Kan; Grace Naswa Makokha; Hiromi Abe-Chayama; Daiki Miki; Michio Imamura; Hidenori Ochi; C Nelson Hayes; Rieko Shimozono; Tomokatsu Iwamura; Hideki Narumi; Tomohiko Suzuki; Mie Kainoh; Tadatsugu Taniguchi; Kazuaki Chayama
Journal:  Antimicrob Agents Chemother       Date:  2017-05-24       Impact factor: 5.191

6.  IFN-α-Induced Downregulation of miR-221 in Dendritic Cells: Implications for HCV Pathogenesis and Treatment.

Authors:  Mohit Sehgal; Marija Zeremski; Andrew H Talal; Rashida Ginwala; Elizabeth Elrod; Arash Grakoui; Qi-Ging Li; Ramila Philip; Zafar K Khan; Pooja Jain
Journal:  J Interferon Cytokine Res       Date:  2015-06-19       Impact factor: 2.607

7.  Positive Regulation of Hepatitis E Virus Replication by MicroRNA-122.

Authors:  Bangari Haldipur; Prudhvi Lal Bhukya; Vidya Arankalle; Kavita Lole
Journal:  J Virol       Date:  2018-05-14       Impact factor: 5.103

8.  Serum microRNA-122 level correlates with virologic responses to pegylated interferon therapy in chronic hepatitis C.

Authors:  Tung-Hung Su; Chen-Hua Liu; Chun-Jen Liu; Chi-Ling Chen; Te-Tien Ting; Tai-Chung Tseng; Pei-Jer Chen; Jia-Horng Kao; Ding-Shinn Chen
Journal:  Proc Natl Acad Sci U S A       Date:  2013-04-23       Impact factor: 11.205

9.  A cross-talk between Hepatitis B virus and host mRNAs confers viral adaptation to liver.

Authors:  Jun Hu; Yaxing Xu; Changfei Li; Junli Hao; Shanxin Peng; Xiaoyu Chu; Dake Zhang; Dongping Xu; Songdong Meng
Journal:  Sci Rep       Date:  2015-07-17       Impact factor: 4.379

10.  Placenta-derived gp96 as a multivalent prophylactic cancer vaccine.

Authors:  Bao Zhao; Yanzhong Wang; Bo Wu; Shan Liu; Erjie Wu; HongXia Fan; MingMing Gui; Lizhao Chen; Changfei Li; Ying Ju; Wei Zhang; Songdong Meng
Journal:  Sci Rep       Date:  2013       Impact factor: 4.379

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.